Legal Representation
Attorney
Noel K. Egnatios
USPTO Deadlines
Application History
45 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 2, 2012 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Jul 2, 2012 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Nov 17, 2011 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 16, 2011 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Nov 10, 2011 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Nov 10, 2011 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 7, 2011 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 6, 2011 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| May 31, 2011 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| May 31, 2011 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 22, 2010 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 21, 2010 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Dec 1, 2010 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Dec 21, 2010 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Dec 1, 2010 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 10, 2010 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Mar 10, 2010 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Mar 10, 2010 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 1, 2009 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Sep 8, 2009 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 19, 2009 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Aug 2, 2009 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Aug 2, 2009 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 23, 2009 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Jul 21, 2009 | I | PAPER RECEIVED | Loading... | |
| Jul 3, 2009 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 2, 2009 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 2, 2009 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 22, 2009 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jun 22, 2009 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 22, 2009 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 15, 2009 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN | Loading... |
| Jun 8, 2009 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY | Loading... |
| May 28, 2009 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| May 27, 2009 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 30, 2009 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 30, 2009 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 30, 2009 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 29, 2009 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 23, 2009 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 23, 2009 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 23, 2009 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 16, 2009 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 30, 2009 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jan 30, 2009 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
biological reagents for laboratory, clinical medical and non-clinical medical research applications
First Use Anywhere:
0
First Use in Commerce:
0
Class 005
Pharmaceutical compositions and preparations for use in therapeutics for human, animal and livestock diseases, namely, use for cardiovascular disease, metabolic disease, autoimmune disease, diabetes, obesity, inflammatory disease, vascular disease, dermatological disease, ocular disease, hematological disease, neurological disease, gastrointestinal disease, respiratory disease, viral and infectious disease, cancer, allergies, allograft rejection, genetic disorders, diseases of the musculoskeletal and nervous system, analgesics and wound healing; pharmaceutical compositions and preparations for the diagnosis, prophylaxis and treatment of human, animal and livestock diseases, namely, cardiovascular disease, metabolic disease, autoimmune disease, diabetes, obesity, inflammatory disease, vascular disease, dermatological disease, ocular disease, hematological disease, neurological disease, gastrointestinal disease, respiratory disease, viral and infectious disease, cancer, allergies, allograft rejection, genetic disorders, diseases of the musculoskeletal and nervous system, analgesics and wound healing; vaccines; pharmaceutical compositions and preparations in the nature of contrast media for use with medical imaging equipment; biological reagents for use in clinical medical and non-clinical medical tests for the diagnosis and measurement of disease progression in human, animal and livestock diseases; biological reagents for use in clinical medical and non-clinical medical imaging
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Translation
The wording "ATRIMER" has no meaning in a foreign language.
Classification
International Classes
001
005